{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T10:41:32Z","timestamp":1776768092062,"version":"3.51.2"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The treatment landscape for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has undergone a profound transformation over the past two decades. The integration of\n                    <jats:italic>BCR-ABL1<\/jats:italic>\n                    tyrosine kinase inhibitors (TKIs) has shifted the paradigm from reliance on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT) towards targeted and immunotherapy-based strategies. Imatinib significantly improved initial complete remission (CR) rates and survival, enabling more patients to proceed to transplant. Second-generation and third-generation TKIs further improved outcomes by targeting most imatinib-resistant mutations, with ponatinib-based regimens achieving deep molecular responses and long-term survival in most patients. Concurrently, immunotherapies like blinatumomab and CAR-T cells have enabled potent chemotherapy-free strategies, yielding high molecular response rates and challenging the necessity of allo-HSCT for all patients. Current evidence supports reserving allo-HSCT for high-risk patients, while those with sustained minimal residual disease (MRD) negativity may be cured with TKI and immunotherapy alone. Future progress hinges on optimizing combinations, integrating novel agents like asciminib and venetoclax, and leveraging MRD and genomic profiling for precision medicine.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1809757","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:23:14Z","timestamp":1776662594000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Toward a chemotherapy and allo-HSCT free future: the evolution of treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia"],"prefix":"10.3389","volume":"17","author":[{"given":"Qixing","family":"Yang","sequence":"first","affiliation":[{"name":"Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0092-8674(87)90007-9","article-title":"Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"51","author":"Hermans","year":"1987","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01277-3","article-title":"Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms","volume":"35","author":"Short","year":"2021","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.1915","article-title":"Progress and innovations in the management of adult acute lymphoblastic leukemia","volume":"4","author":"Jabbour","year":"2018","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.2009.011221","article-title":"Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial","volume":"95","author":"Ribera","year":"2010","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24137","article-title":"Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"90","author":"Lim","year":"2015","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.118588","article-title":"Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1287","article-title":"Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09\/00","volume":"28","author":"Bassan","year":"2010","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016001495","article-title":"US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in philadelphia chromosome positive ALL","volume":"1","author":"Ravandi","year":"2016","journal-title":"Blood Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.5868","article-title":"Effect of dasatinib vs imatinib in the treatment of pediatric philadelphia chromosome-positive acute lymphoblastic leukemia: A randomized clinical trial","volume":"6","author":"Shen","year":"2020","journal-title":"JAMA Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23624","article-title":"Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia","volume":"89","author":"Benjamini","year":"2014","journal-title":"Am J Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21615","article-title":"Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study","volume":"85","author":"Lilly","year":"2010","journal-title":"Am J Hematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3324\/haematol.2018.188987","article-title":"Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia","volume":"104","author":"Hughes","year":"2019","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/ajh.26816","article-title":"Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results","volume":"98","author":"Kantarjian","year":"2023","journal-title":"Am J Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007764","article-title":"Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"6","author":"Ribera","year":"2022","journal-title":"Blood Adv"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33529","article-title":"Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02497-y","article-title":"Ponatinib vs. Imatinib as frontline treatment for philadelphia chromosome-positive acute lymphoblastic leukemia: A matching adjusted indirect comparison","volume":"40","author":"Ribera","year":"2023","journal-title":"Adv Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30231","article-title":"Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis","volume":"122","author":"Sasaki","year":"2016","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-052746","article-title":"Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell\u2019Adulto (GIMEMA) LAL0201-B protocol","volume":"109","author":"Vignetti","year":"2007","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004607","article-title":"Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"6","author":"Sugiura","year":"2022","journal-title":"Blood Adv"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004813","article-title":"Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL","volume":"5","author":"Wieduwilt","year":"2021","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16661","article-title":"An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"189","author":"Li","year":"2020","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.260935","article-title":"A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol","volume":"106","author":"Chiaretti","year":"2021","journal-title":"Haematologica"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004821","article-title":"INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia","volume":"6","author":"Martinelli","year":"2022","journal-title":"Blood Adv"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1182\/blood-2023-182997","article-title":"A phase II study of low-intensity chemotherapy (Mini-hyper-CVD) and ponatinib followed by blinatumomab and ponatinib in patients with philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"142","author":"Jen","year":"2023","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167883","article-title":"A phase II study of the sequential combination of low-intensity chemotherapy (mini-hyper-CVD) and ponatinib followed by blinatumomab and ponatinib in patients with philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)","volume":"140","author":"Nguyen","year":"2022","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs imatinib in frontline philadelphia chromosome-positive acute lymphoblastic leukemia: A randomized clinical trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"JAMA"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70780","article-title":"Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) in patients with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia: A comparison of ponatinib versus imatinib","volume":"14","author":"Ashaye","year":"2025","journal-title":"Cancer Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01221-z","article-title":"Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee","volume":"15","author":"Januzzi","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284853","article-title":"Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20+ Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical models","volume":"109","author":"Domka","year":"2024","journal-title":"Haematologica"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025800","article-title":"Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia","volume":"145","author":"Luskin","year":"2025","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1182\/blood-2023-185578","article-title":"Efficacy and safety of asciminib in chinese patients with philadelphia chromosome(Ph)-positive leukaemias","volume":"142","author":"Cheung","year":"2023","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016665","article-title":"Asciminib for relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"9","author":"Chanut","year":"2025","journal-title":"Blood Adv"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008216","article-title":"Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in Ph+ acute lymphoblastic leukemia","volume":"7","author":"Advani","year":"2023","journal-title":"Blood Adv"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult philadelphia-positive ALL","volume":"42","author":"Fo\u00e0","year":"2024","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00272","article-title":"Results of the simultaneous combination of ponatinib and blinatumomab in philadelphia chromosome-positive ALL","volume":"42","author":"Kantarjian","year":"2024","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1182\/blood-2023-186139","article-title":"Frontline combination of 3 rd generation TKI olverembatinib and blinatumomab for ph+\/ph-like ALL patients","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7550","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32558","article-title":"Blinatumomab compared with standard of care for the treatment of adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia","volume":"126","author":"Rambaldi","year":"2020","journal-title":"Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2014.05.022","article-title":"Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"16","author":"Saito","year":"2014","journal-title":"Cytotherapy"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009072","article-title":"Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia","volume":"7","author":"Chen","year":"2023","journal-title":"Blood Adv"},{"key":"B50","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12916-026-04755-6","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory Philadelphia chromosome-positive B cell acute lymphoblastic leukemia: a multicenter retrospective study","volume":"24","author":"Yu","year":"2026","journal-title":"BMC Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.0674","article-title":"Dasatinib and CAR T-cell therapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: A nonrandomized clinical trial","volume":"11","author":"Zhang","year":"2025","journal-title":"JAMA Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"6875","DOI":"10.1182\/blood-2023-178477","article-title":"High response rates following point-of-care anti-CD19 CAR T-cell therapy in adults with relapsed\/refractory acute B lymphoblastic leukemia","volume":"142","author":"Shalev Fried","year":"2023","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41409-020-0982-6","article-title":"Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells","volume":"56","author":"Gu","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01845-w","article-title":"CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"58","author":"Yao","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0802-5","article-title":"Inotuzumab ozogamicin: First global approval","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26238","article-title":"Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia","volume":"96","author":"Jain","year":"2021","journal-title":"Am J Hematol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33321","article-title":"Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed\/refractory acute lymphoblastic leukemia","volume":"127","author":"Stock","year":"2021","journal-title":"Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.70026","article-title":"Efficacy and safety of the third-generation tyrosine kinase inhibitor olverembatinib in combination with inotuzumab ozogamicin for the treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia patients with refractory\/relapsed disease or persistent minimal residual disease bridging to hematopoietic stem cell transplantation","volume":"100","author":"Zhang","year":"2025","journal-title":"Am J Hematol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"354ra114","DOI":"10.1126\/scitranslmed.aaf5309","article-title":"Targeting BCL-2 and ABL\/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"8","author":"Leonard","year":"2016","journal-title":"Sci Transl Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001416","article-title":"Cotargeting BCL-2 and MCL-1 in high-risk B-ALL","volume":"4","author":"Moujalled","year":"2020","journal-title":"Blood Adv"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26175","article-title":"An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"96","author":"Short","year":"2021","journal-title":"Am J Hematol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02696-2","article-title":"Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial","volume":"39","author":"Gong","year":"2025","journal-title":"Leukemia"},{"key":"B64","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41408-022-00621-9","article-title":"Venetoclax-ponatinib for T315I\/compound-mutated Ph+ acute lymphoblastic leukemia","volume":"12","author":"Wang","year":"2022","journal-title":"Blood Cancer J"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1182\/blood-2023-174216","article-title":"A phase I study of venetoclax in combination with inotuzumab ozogamicin for relapsed or refractory ALL in adults","volume":"142","author":"Luskin","year":"2023","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27237","article-title":"Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission","volume":"99","author":"Nishiwaki","year":"2024","journal-title":"Am J Hematol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34710","article-title":"Chemotherapy with the use of next-generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"129","author":"Xie","year":"2023","journal-title":"Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016194","article-title":"The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis","volume":"140","author":"Ghobadi","year":"2022","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14167","article-title":"Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"110","author":"Akahoshi","year":"2019","journal-title":"Cancer Sci"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27378","article-title":"Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"99","author":"Othman","year":"2024","journal-title":"Am J Hematol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004685","article-title":"Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL","volume":"136","author":"Saini","year":"2020","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27516","article-title":"A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre-transplantation for Ph+ acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study","volume":"100","author":"Liu","year":"2025","journal-title":"Am J Hematol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01206-5","article-title":"Stopping tyrosine kinase inhibitors started after allogeneic HCT in patients with Philadelphia chromosome-positive leukemia","volume":"56","author":"Nakasone","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.281","article-title":"Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL","volume":"50","author":"Kim","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-796862","article-title":"Genomic CDKN2A\/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation","volume":"131","author":"Pfeifer","year":"2018","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-016-0270-5","article-title":"Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"9","author":"Xu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj8803","article-title":"ERG and c-MYC regulate a critical gene network in BCR::ABL1-driven B cell acute lymphoblastic leukemia","volume":"10","author":"Behrens","year":"2024","journal-title":"Sci Adv"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2644","article-title":"Targeting CDK6 and BCL2 exploits the \u201cMYB addiction\u201d of Ph+ acute lymphoblastic leukemia","volume":"78","author":"De Dominici","year":"2018","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15580","article-title":"SLC2A5 overexpression in childhood Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"183","author":"Zhao","year":"2018","journal-title":"Br J Haematol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1522293","article-title":"A comprehensive prognostic and immune analysis of LAPTM4B in pan-cancer and Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"16","author":"Zhou","year":"2025","journal-title":"Front Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41467-023-44270-3","article-title":"Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"B82","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1038\/s41467-020-16927-w","article-title":"Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"11","author":"Abdelrasoul","year":"2020","journal-title":"Nat Commun"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.250","article-title":"SHP2 is required for BCR-ABL1-induced hematologic neoplasia","volume":"32","author":"Gu","year":"2018","journal-title":"Leukemia"},{"key":"B84","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12964-023-01039-x","article-title":"Jak2\/STAT6\/c-Myc pathway is vital to the pathogenicity of Philadelphia-positive acute lymphoblastic leukemia caused by P190BCR-ABL","volume":"21","author":"Qin","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0195","article-title":"Targeting STAT5 or STAT5-regulated pathways suppresses leukemogenesis of Ph+ acute lymphoblastic leukemia","volume":"78","author":"Minieri","year":"2018","journal-title":"Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/1535-7163.MCT-14-1065","article-title":"Specific antileukemic activity of PD0332991, a CDK4\/6 inhibitor, against Philadelphia chromosome-positive lymphoid leukemia","volume":"15","author":"Nemoto","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B87","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-020-00912-3","article-title":"Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition","volume":"13","author":"Xiao","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000701","article-title":"Targeting apoptosis pathways with BCL2 and MDM2 inhibitors in adult B-cell acute lymphoblastic leukemia","volume":"6","author":"Hohtari","year":"2022","journal-title":"Hemasphere"},{"key":"B89","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/leu.2017.174","article-title":"HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia","volume":"32","author":"Tharkar-Promod","year":"2018","journal-title":"Leukemia"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2021.07.009","article-title":"Oncogene-independent resistance in Philadelphia chromosome - positive (Ph+) acute lymphoblastic leukemia (ALL) is mediated by activation of AKT\/mTOR pathway","volume":"23","author":"Mian","year":"2021","journal-title":"Neoplasia"},{"key":"B91","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41420-021-00523-y","article-title":"IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform","volume":"7","author":"Harama","year":"2021","journal-title":"Cell Death Discov"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-466482","article-title":"Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy","volume":"122","author":"Ravandi","year":"2013","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052116","article-title":"Comprehensive analysis of high-sensitive flow cytometry and molecular mensurable residual disease in Philadelphia chromosome-positive acute leukemia","volume":"26","author":"de Azambuja","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00108","article-title":"Significance of measurable residual disease in adult Philadelphia chromosome-positive ALL: A GRAAPH-2014 study","volume":"42","author":"Kim","year":"2024","journal-title":"J Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.176917","article-title":"Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin\/T-cell receptor and BCR\/ABL1 methodologies","volume":"103","author":"Cazzaniga","year":"2018","journal-title":"Haematologica"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26949","article-title":"Ultrasensitive NGS MRD assessment in Ph+\u2009ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1","volume":"98","author":"Short","year":"2023","journal-title":"Am J Hematol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01668-0","article-title":"Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease","volume":"36","author":"Zuna","year":"2022","journal-title":"Leukemia"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-749978","article-title":"Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology","volume":"129","author":"Hovorkova","year":"2017","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1809757\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T09:48:16Z","timestamp":1776764896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1809757\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":98,"alternative-id":["10.3389\/fimmu.2026.1809757"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1809757","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"1809757"}}